WUXI YAOMING UNITED BIOTECHNOLOGY CO. LTD Mediaroom

The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development

SINGAPORE, Sept. 26, 2025 /PRNewswire/ -- The 2025 BPD (Biopharmaceutical Bioprocess Development) S...

2025-09-27 10:45 3615

WuXi XDC Included in MSCI China All Share Index

SHANGHAI, Aug. 8, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a le...

2025-08-08 17:32 1642

WuXi XDC Achieves GMP Release of Newly Launched DP3 Facility at Wuxi Site, Scaling Further Drug Product Manufacturing Capacity

WUXI, China, Aug. 4, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a...

2025-08-05 10:13 1483

WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing

SHANGHAI and SINGAPORE, July 1, 2025 /PRNewswire/ -- On June 30, WuXi XDC Cayman Inc. ("WuXi XDC", ...

2025-07-01 17:44 4080

WuXi XDC Received Multiple Awards from 2025 Extel (previously "Institutional Investor") Ranking in Diverse Categories

SHANGHAI, May 19, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a le...

2025-05-20 09:44 2987

WuXi XDC Received Multiple Awards from 2025 Extel (previously

WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024

* Revenue increased by 90.8% YoY to RMB 4,052 million * Gross profit grew by 121.6% YoY to RMB 1...

2025-03-24 22:45 3176

WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024

WuXi XDC Wins Multiple Awards at Asia-Pacific Biopharma Excellence Awards 2025

SHANGHAI, March 13, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock ...

2025-03-13 13:54 2518

WuXi XDC Wins Multiple Awards at Asia-Pacific Biopharma Excellence Awards 2025

WuXi XDC and AbTis Announce Strategic Partnership to Advance Next-Generation ADCs

SHANGHAI and SEOUL, South Korea , March 11, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" o...

2025-03-11 21:20 1980

WuXi XDC and AbTis Announce Strategic Partnership to Advance Next-Generation ADCs

WuXi XDC and LigaChem Biosciences Strengthen Partnership with Expanded MOU to Accelerate ADC Development

SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock c...

2025-02-25 18:34 1822

WuXi XDC and LigaChem Biosciences Strengthen Partnership with Expanded MOU to Accelerate ADC Development

WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards

SHANGHAI and SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Compa...

2024-11-08 11:27 2724

WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards

WuXi XDC Reports Strong Business Updates with Superior Financial Results in 1H 2024: Poised for Future Growth

* Revenue surged by 67.6% YoY to RMB 1,665 million * Gross profit surged by 133.4% to RMB 535 mi...

2024-08-20 23:05 3393

WuXi XDC Reports Strong Business Updates with Superior Financial Results in 1H 2024: Poised for Future Growth

WuXi XDC Delivers Outstanding Performance in 2023 with over 110% Year-On-Year Growth for Both Revenue and Adjusted Net Profit and Achieves Significant Corporate Milestones

* Revenue reached RMB 2,124 million, an increase of 114% compared with Year 2022 * Adjusted net...

2024-03-25 21:39 3107

WuXi XDC Delivers Outstanding Performance in 2023 with over 110% Year-On-Year Growth for Both Revenue and Adjusted Net Profit and Achieves Significant Corporate Milestones

WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development

SHANGHAI, Jan. 30, 2024 /PRNewswire/ -- WuXi XDC (2268.HK), a leading global Contract Research, Dev...

2024-01-31 10:43 3533

Latest News

The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development

WuXi XDC Included in MSCI China All Share Index

WuXi XDC Achieves GMP Release of Newly Launched DP3 Facility at Wuxi Site, Scaling Further Drug Product Manufacturing Capacity

WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing

WuXi XDC Received Multiple Awards from 2025 Extel (previously "Institutional Investor") Ranking in Diverse Categories

WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024

WuXi XDC Wins Multiple Awards at Asia-Pacific Biopharma Excellence Awards 2025

WuXi XDC and AbTis Announce Strategic Partnership to Advance Next-Generation ADCs

WuXi XDC and LigaChem Biosciences Strengthen Partnership with Expanded MOU to Accelerate ADC Development

WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards

WuXi XDC Reports Strong Business Updates with Superior Financial Results in 1H 2024: Poised for Future Growth

WuXi XDC Delivers Outstanding Performance in 2023 with over 110% Year-On-Year Growth for Both Revenue and Adjusted Net Profit and Achieves Significant Corporate Milestones

WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development

WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates (ADCs)

WuXi XDC Enters into Partnership Agreement with IntoCell, Enabling Clients to Accelerate ADC Discovery and Development

WuXi XDC Successfully Listed on the Main Board of Hong Kong Stock Exchange

WuXi XDC Named Best CDMO Winner at 2023 World ADC Awards

WuXi XDC and HKSTP Join Forces to Promote Development of Bioconjugate Drug Industry in Hong Kong

WuXi XDC Launches New Commercial Manufacturing Facilities

WuXi XDC and Boostimmune Sign MOU for Integrated Services